SwedenSweden

InDex Closes Financing Round

07.06.2004

Stockholm - The Swedestart Life Science KB fund, managed by CapMan, invested Euro3.9 million in InDex Pharmaceuticals AB, with an option to invest another Euro1.6 million. With this investment the Swedestart fund becomes one of the major shareholders in the Stockholm-based company, together with Life Equity Sweden and SEB Företagsinvest. The funds invested will be used to finance InDex' current research projects including Kappaproct® for the treatment of the inflammatory bowel disease, which is currently in phase II clinical trials in five European countries.
“We are very enthusiastic about reaching this agreement with CapMan. Our collaboration with Serono concerning Kappa-proct runs according to plan and we can now put more resources behind many of our research and product development activities in the company,” said Svante Rasmuson, CEO of InDex.
“InDex has an interesting pipeline of products under development, including Kappaproct and a new test for diagnosing IBD subtypes,” commented Björn Nor-denvall, investment director at CapMan. InDex develops RNA blocking drugs as well as diagnostic/prognostic tools inflammation and cancer.

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/index-closes-financing-round.html

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)3.26 SEK5.16%
  • OREXO (S)121.00 SEK4.54%
  • CO.DON (D)2.88 EUR4.35%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • EPIGENOMICS (D)3.06 EUR-8.38%

TOP

  • CELLECTIS (F)13.54 EUR112.6%
  • SANTHERA (CH)68.40 CHF107.3%
  • ADDEX (CH)4.40 CHF101.8%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.98 EUR-50.3%
  • VERONA PHARMA (UK)1.15 GBP-45.2%

TOP

  • SANTHERA (CH)68.40 CHF3009.1%
  • GW PHARMACEUTICALS (UK)439.50 GBP835.1%
  • PAION (D)2.80 EUR324.2%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events